BMB-101 is under clinical development by Bright Minds Biosciences and currently in Phase I for Alzheimer’s Disease. According to GlobalData, Phase I drugs for Alzheimer’s Disease have a 63% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how BMB-101’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

BMB-101 overview

BMA-101 is under development for the treatment of undisclosed seizure disorder, Dravet Syndrome opioid use disorder, binge eating disorder and Alzheimer's disease. It acts by targeting 5-hydroxytryptamine receptor 2C (5 HT2C). It is administered through oral route in the form of liquid. 

Bright Minds Biosciences overview

Bright Minds Biosciences (Bright Minds) is a biotechnology company that discovers and develops treatments for neuropsychiatry disorders, epilepsy, and pain. The company is investigating serotonin agonists targeting 5-HT2C, 5-HT2A/C, and 5-HT2A receptors to treat undisclosed seizure, opioid use, binge eating disorder; Alzheimer’s disease; depression; post-traumatic stress disorder (PTSD); and undisclosed chronic pain disorder. It utilizes intelligent drug design and advanced molecular modelling technology to develop its products. The company works in collaboration with the National Institutes of Health (NIH), University Of Texas Medical Branch, Medical College of Wisconsin and Katholieke Universities Leuven. Bright Minds is headquartered in New York, New York City, the US.

For a complete picture of BMB-101’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 20 May 2024

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.